**BLOOD PRODUCT FACT SHEET: C1 ESTERASE INHIBITOR (Berinert P®)**

**Consent Required** | Yes
---|---
**Pre-Transfusion Sample** | Not Required
**Approval Requirements** | Hematopathologist approval required unless ordered by clinical immunologist/allergist.
**Product Description** | Sterile, stable, purified, freeze-dried concentrate of C1 esterase inhibitor prepared from pooled human plasma. Heat treated to reduce viral transmission. Contains no preservatives. Available in 500 U and 1500 U vial size. 1 U is equivalent to the C1-esterase activity of 1 mL fresh plasma. Supplied as a lyophilized product with sterile water diluent. Reconstituted in Transfusion Medicine and issued in a syringe or transfer bag as requested by clinical staff.
**Clinical Indications** | Treatment of acute abdominal, facial or laryngeal attacks of Hereditary Angioedema (HAE) of moderate to severe intensity.
**Contraindications** | None known.
**Risks** | Allergic reactions, anaphylactic reactions, rise in temperature, transmission of infection. Vaccination against hepatitis A and hepatitis B should be considered for patients who regularly receive C1 esterase inhibitor. C1 esterase inhibitor should be given to a pregnant or lactating woman only if clearly needed.
**Dosage** | **Infant/Pediatric/Adult:** 20 Units/Kilogram body weight
**Administration** | **Administer** pre medications as ordered. **Refer** to:
- Procedure: Administering Medications Using IV Push Method
- Product monograph **Administer** by slow intravenous injection at a rate of 4 mL/min or via syringe at a rate not to exceed 4 mL/min (240 mL/h). C1 esterase inhibitor **must be** administered **immediately** after arrival in patient care unit.
**Compatible Solution** | The manufacturer does not recommend any compatible fluids. **Flush** the line before and after administration with 0.9% Normal Saline only.
**Infusion Rates** | **Infusion Rate** of 4 mL/min (240 mL/hr).
**Monitoring** | **Observe** for signs and symptoms of allergic/anaphylactic reactions. In the event of a suspected transfusion reaction, **STOP** the transfusion and refer to Transfusion Reaction Procedure & Quick Reference guide and complete the Transfusion Reaction Report Form.
**Storage Conditions** | Stored in a monitored blood product storage refrigerator at 1 – 6 °C. **Return** C1 esterase inhibitor and Transfusion Record to Transfusion Medicine within 20 minutes from time of issue if there are any delays in administration. **Do NOT** refrigerate on nursing unit.
**References** | Product monograph: **Berinert**, CSL Behring Canada Inc, June 2012.
Version History

<table>
<thead>
<tr>
<th>DATE</th>
<th>DOCUMENT NUMBER and TITLE</th>
<th>ACTION TAKEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>05-Mar-2019</td>
<td>C-05-14-60112 Blood Product Fact Sheet: C1 Esterase Inhibitor</td>
<td>Approved at: CW Transfusion Medicine</td>
</tr>
</tbody>
</table>

Disclaimer

This document is intended for use within BC Children’s and BC Women’s Hospitals only. Any other use or reliance is at your sole risk. The content does not constitute and is not in substitution of professional medical advice. Provincial Health Services Authority (PHSA) assumes no liability arising from use or reliance on this document. This document is protected by copyright and may only be reprinted in whole or in part with the prior written approval of PHSA.